[HDL and CETP in atherogenesis].

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Optimal low-density lipoprotein (LDL) cholesterol treatment with statins leaves residual cardiovascular risk.
• High-density lipoprotein (HDL) cholesterol levels correlate inversely with cardiovascular events, but HDL's role is complex and context-dependent.
• HDL particles are heterogeneous, and under certain conditions, can promote atherogenesis and inflammation.

Purpose of the Study:

• To evaluate the efficacy and safety of novel cholesteryl ester transfer protein (CETP) inhibitors in managing residual cardiovascular risk.
• To investigate whether increasing HDL cholesterol concentrations through CETP inhibition improves HDL functionality and reduces cardiovascular events.
• To address the open question of functional characterization of HDL produced by CETP inhibition.

Main Methods:

• Review of epidemiological studies and clinical trials on HDL cholesterol and cardiovascular events.
• Analysis of the impact of CETP inhibitors (e.g., torcetrapib, dalcetrapib, anacetrapib) on HDL levels, blood pressure, and cardiovascular outcomes.
• Exploration of the functional properties of HDL particles generated by CETP inhibition.

Main Results:

• Previous CETP inhibitor (torcetrapib) increased blood pressure and cardiovascular events despite raising HDL.
• The effects of newer CETP inhibitors on blood pressure are not fully established.
• Increased HDL cholesterol does not automatically equate to improved HDL function or reduced cardiovascular risk.

Conclusions:

• CETP inhibition is a strategy to raise HDL cholesterol, but its clinical benefit requires further elucidation.
• Functional characterization of HDL produced by CETP inhibition is crucial.
• Ongoing clinical endpoint studies with new CETP inhibitors are essential to determine their role in reducing cardiovascular events.